Name,Category,Begin Date,End Date,Note
Abdominal Pain and Fatigue,Milestones,2023-02-01,,Nonspecific symptoms 2 months
CT Abdomen,Biomarker Assess,2023-02-10,,5cm liver mass discovered
MRI Liver with Contrast,Biomarker Assess,2023-02-17,,Intrahepatic cholangiocarcinoma suspected
Liver Biopsy,Biomarker Assess,2023-02-22,,Intrahepatic CCA confirmed
CA 19-9 Baseline,Biomarker Assess,2023-02-25,,Elevated at 450 U/mL
Molecular Profiling Sent,Biomarker Assess,2023-02-28,,Foundation One ordered
Staging Laparoscopy,Biomarker Assess,2023-03-08,,No peritoneal disease
Molecular Results,Biomarker Assess,2023-03-15,,FGFR2 fusion detected IDH1 wild-type
Multidisciplinary Tumor Board,Milestones,2023-03-20,,Deemed resectable
Left Hepatectomy,Milestones,2023-04-05,,R0 resection margins negative
Pathology Final,Biomarker Assess,2023-04-12,,T2N0 no nodes involved
Adjuvant Capecitabine,Line 1 treatment,2023-05-10,2023-11-10,6 months per BILCAP trial
CA 19-9 Normalized,Biomarker Assess,2023-06-15,,Down to 28 U/mL
3-Month Surveillance CT,Milestones,2023-08-10,,No evidence of recurrence
6-Month Surveillance,Milestones,2023-11-10,,NED continues
12-Month Surveillance,Milestones,2024-04-05,,Remains disease-free
